Logo

Sanofi's Dupixent (dupilumab) Receives NICE Recommendation for the Treatment of Severe Asthma

Share this

Sanofi's Dupixent (dupilumab) Receives NICE Recommendation for the Treatment of Severe Asthma

Shots:

  • The NICE has issued a final appraisal determination (FAD) which recommends Dupixent (dupilumab) as an add-on maintenance treatment for severe asthma
  • The NICE recommendation is based on a LIBERTY ASTHMA QUEST trial evaluating Dupixent vs PBO in patients with severe asthma with high exacerbation rates and high biomarkers indicating type 2 inflammation
  • The results showed a ~67% reduction in severe asthma attacks & 50% hospitalisations/A&E visits. The therapy also improved lung function (FEV1) & eliminated the use of OCS  (52% vs 29%) in patients with type 2 inflammation. The publication date of a NICE final guidance for dupilumab within NHS England is expected in early Dec.

  | Ref: PR Newswire | Image: Evaluate Pharma

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions